3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
2
Urinary Bladder Neoplasms
1
Interventions
Gemcitabine
28
Cisplatin
26
Mitomycin
18
BCG Vaccine
12
pembrolizumab
9
Paclitaxel
8
Doxorubicin
7
Docetaxel
7
5-aminolevulinic acid hexyl ester
7
apaziquone
6
Carboplatin
6
vinflunine
5
enfortumab vedotin
5
atezolizumab
5
Vinblastine
5
Radiotherapy
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Fluorouracil
5
Cystectomy
5
durvalumab
4
Surgical Procedures, Operative
4
Nivolumab
4
Transurethral Resection of Bladder
3
Specimen Handling
3
Selenium
3
Radiation
3
Filgrastim
3
Cystoscopy
3
BCG Connaught
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urinary Bladder Neoplasms
×
VB4-845
×
Clear all
NCT02449239
2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3
Completed
133 enrolled
18 charts